Pharmaceutical Executive
by Pharmaceutical Executive Podcast
Pharmaceutical Executive Daily: FDA Approves Three New Therapies
About this podcast
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Episodes
The newest 50 of 487 episodes
- Pharmaceutical Executive Daily: FDA Approves Three New Therapies · 3 minFDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron…
- The Ron Lanton Report: Ossium Health's Bone Marrow Bank · 23 minOssium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product…
- Pharmaceutical Executive Daily: FDA Shelves CNPV Program · 2 minFDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity…
- Pharmaceutical Executive Daily: Moderna Outlines Growth Plan at 2026 Analyst Day · 3 minModerna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s…
- Pharmaceutical Executive Daily: FDA Approves Pimjetmi · 2 minFDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite…
- Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist · 2 minFDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists…
- Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc. · 2 minargenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the…
- Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro · 2 minHims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants…
- Pharmaceutical Executive Daily: Egetis Sells Priority Review Voucher for $190 Million · 2 minANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter…
- Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie · 3 minHow microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with…
- Pharmaceutical Executive Daily: FDA Approves Voceryq · 3 minFDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital…
- States Take Center Stage in the Drug Pricing Fight · 32 minIn this episode of the Pharmaceutical Executive podcast, Scott LaGanga, executive vice president of state advocacy at PhRMA, discusses the expanding influence of state…
- Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb · 3 minBristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI…
- The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki · 38 minPharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
- Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act · 3 minTreasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R…
- Building Biopharma Manufacturing for Speed, Scale, and Flexibility · 37 minBiopharma manufacturing today is being asked to move faster, accommodate increasingly complex modalities, and respond more readily to changing development timelines and demand…
- Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S. · 3 minFDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’…
- Pharmaceutical Executive Daily: FDA Approves Hibsago · 3 minA new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis…
- Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli · 3 minMETiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA…
- Pharmaceutical Executive Daily: Hansoh Pharma Enters Collaboration and License Agreement with Roche for Broad Portfolio of ADCs · 3 minMerck KGaA, Darmstadt, Germany, acquires Silence Therapeutics for $1.3 billion, Hansoh Pharma and Roche expand their ADC partnership in a deal worth over $15 billion, and an EMA…
- Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology · 2 minGilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug…
- Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy with Roche · 3 minExperts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with…
- Pharmaceutical Executive Daily: Thomas Appio Named Interim CEO of Bausch + Lomb · 3 minBausch + Lomb names Thomas Appio interim CEO as Brent Saunders departs, a Pharm Exec interview explores how AI is reshaping entry-level apprenticeship in professional services…
- Pharmaceutical Executive Daily: FDA Approves Tecentriq · 3 minThe FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines…
- Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher · 3 minUltragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying…
- Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab · 3 minCaribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a…
- Pharmaceutical Executive Daily: What HCP Engagement Actually Looks Like · 3 minShionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala…
- AI and Patient Recruitment: Can Predictive Promise Drive True Transformation? · 27 minCan artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this…
- Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership · 3 minJewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's…
- Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909 · 3 minFoghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit…
- Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos · 3 minRegeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael…
- Pharmaceutical Executive Daily: Peptide Ruling Stalls · 3 minNovo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide…
- A Leadership Call to Action for Biotech · 36 minIn this episode of Leading Edge with Ken Banta, Jeremy Levin, D.Phil, MB BChir, co-founder and executive chairman of Ovid Therapeutics, joins Banta, The Vanguard Network founder…
- Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming · 3 minNew U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers…
- Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal · 3 minMerck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the…
- Pharmaceutical Executive Daily: FDA Approves Welireg Plus Lenvima · 3 minFDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa…
- Pharmaceutical Executive Daily: FDA Approves Onswik · 3 minInnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing…
- Pharmaceutical Executive Daily: Mike Doustdar Open to Direct Listing for Novo Shares · 3 minEVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real…
- Pharmaceutical Executive Daily: Nine European Drugmakers Note Concern Over Region's Pharma Investments · 3 minNine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat…
- Pharmaceutical Executive Daily: FDA Approves Fayuvi · 3 minFDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a…
- Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia · 3 minFDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis…
- Pharmaceutical Executive Daily: Novo Partners with Anthropic · 3 minNovo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining…
- Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership · 3 minGSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma…
- Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand · 3 minCellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of…
- Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy · 3 minNovartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather…
- 340B Under Pressure: Inside Pharma's Push for Greater Clarity · 33 minIn this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to examine the growing stakes surrounding the 340B…
- Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B · 3 minAptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity…
- Pharmaceutical Executive Daily: FDA Approves Zanvastro · 3 minIonis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical Executive’s weekly biotech roundup gathers analyst reaction to…








